Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 5Phase 1/2 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Terminated 5Completed 4Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1CNS 1

Conditions

Uterine Cervical Neoplasms 1Neoplasm Metastasis 1Brain Neoplasms 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 20venetoclax 19Radiotherapy 19Gemcitabine 19Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12Azacitidine 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Ado-Trastuzumab Emtansine × Clear all
NCT05593094 2026-05-26

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Hoffmann-La Roche

Phase 1/2 Active not recruiting
210 enrolled
CNS

Brain Neoplasms

NCT05081609 2026-02-24

IL Believe

Ascendis Pharma A/S

Phase 1/2 Active not recruiting
320 enrolled
Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡